Who are antabuse (disulfiram)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antabuse, disulfiram plus lorazepam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antabuse-disulfiram.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

antabuse (disulfiram) — Competitive Intelligence Brief

antabuse (disulfiram) (antabuse (disulfiram)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldehyde dehydrogenase inhibitor. Area: Psychiatry / Addiction Medicine.

marketed Aldehyde dehydrogenase inhibitor Aldehyde dehydrogenase (ALDH) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

antabuse (disulfiram) (antabuse (disulfiram)) — Psykiatrisk Center Gentofte. Disulfiram inhibits the enzyme aldehyde dehydrogenase, causing toxic acetaldehyde accumulation when alcohol is consumed, producing an aversive reaction that discourages drinking.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
antabuse (disulfiram) TARGET	antabuse (disulfiram)	Psykiatrisk Center Gentofte	marketed	Aldehyde dehydrogenase inhibitor	Aldehyde dehydrogenase (ALDH)
Antabuse	DISULFIRAM		marketed	Aldehyde Dehydrogenase Inhibitor [EPC]	Lysyl oxidase homolog 4	1951-01-01
disulfiram plus lorazepam	disulfiram plus lorazepam	University of New Mexico	marketed	Aldehyde dehydrogenase inhibitor plus benzodiazepine	Aldehyde dehydrogenase (ALDH); GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldehyde dehydrogenase inhibitor class)

Psykiatrisk Center Gentofte · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). antabuse (disulfiram) — Competitive Intelligence Brief. https://druglandscape.com/ci/antabuse-disulfiram. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab